Details for Patent: 9,815,827
✉ Email this page to a colleague
Which drugs does patent 9,815,827 protect, and when does it expire?
Patent 9,815,827 protects LATUDA and is included in one NDA.
This patent has eleven patent family members in seven countries.
Summary for Patent: 9,815,827
Title: | Agent for treatment of schizophrenia |
Abstract: | The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmet- hyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily dose of 5 mg to 120 mg once a day to a patient with schizophrenia, and a therapeutic agent to be used in said method. |
Inventor(s): | Nakamura; Mitsutaka (Kawanishi, JP), Ogasa; Masaaki (Tokyo, JP), Sami; Shunsuke (Kawasaki, JP) |
Assignee: | Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP) |
Application Number: | 14/471,919 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,815,827 |
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,815,827
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-003 | Dec 7, 2011 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER | ⤷ Sign Up | |||
Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-003 | Dec 7, 2011 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SCHIZOPHRENIA | ⤷ Sign Up | |||
Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-001 | Oct 28, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER | ⤷ Sign Up | |||
Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-001 | Oct 28, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SCHIZOPHRENIA | ⤷ Sign Up | |||
Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-005 | Jul 12, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER | ⤷ Sign Up | |||
Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-005 | Jul 12, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SCHIZOPHRENIA | ⤷ Sign Up | |||
Sunovion Pharms Inc | LATUDA | lurasidone hydrochloride | TABLET;ORAL | 200603-002 | Oct 28, 2010 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF SCHIZOPHRENIA | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,815,827
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 431147 | ⤷ Sign Up | |||
Australia | 2003257589 | ⤷ Sign Up | |||
Germany | 60327634 | ⤷ Sign Up | |||
European Patent Office | 1535616 | ⤷ Sign Up | |||
European Patent Office | 1944030 | ⤷ Sign Up | |||
European Patent Office | 2295061 | ⤷ Sign Up | |||
Spain | 2326078 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |